enGene’s (ENGN) Buy Rating Reiterated at HC Wainwright

by · The Cerbat Gem

HC Wainwright reiterated their buy rating on shares of enGene (NASDAQ:ENGN – Free Report) in a report issued on Tuesday,Benzinga reports. HC Wainwright currently has a $4.00 target price on the stock.

Several other research firms have also recently issued reports on ENGN. Morgan Stanley cut enGene from an “equal weight” rating to an “underweight” rating and set a $3.00 price objective on the stock. in a report on Thursday, June 18th. UBS Group decreased their target price on enGene from $9.00 to $2.00 and set a “neutral” rating on the stock in a research report on Thursday, May 14th. Weiss Ratings reiterated a “sell (e+)” rating on shares of enGene in a research report on Wednesday, August 12th. Finally, Wall Street Zen upgraded enGene from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 15th. Four equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, enGene presently has a consensus rating of “Hold” and an average price target of $11.05.

Read Our Latest Analysis on enGene

enGene Stock Performance

NASDAQ:ENGN opened at $1.77 on Tuesday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 12.57 and a current ratio of 10.21. The company has a fifty day moving average of $1.83 and a two-hundred day moving average of $3.93. The stock has a market capitalization of $118.57 million, a PE ratio of -1.57 and a beta of -0.28. enGene has a fifty-two week low of $1.40 and a fifty-two week high of $12.25.

enGene (NASDAQ:ENGN – Get Free Report) last announced its earnings results on Tuesday, September 8th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.04). As a group, research analysts forecast that enGene will post -1.83 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of ENGN. Millennium Management LLC increased its stake in shares of enGene by 57.3% in the 3rd quarter. Millennium Management LLC now owns 20,502 shares of the company’s stock worth $140,000 after acquiring an additional 7,472 shares during the last quarter. Raymond James Financial Inc. raised its holdings in shares of enGene by 383.6% during the 3rd quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock worth $68,000 after acquiring an additional 7,932 shares during the period. Cresset Asset Management LLC acquired a new position in shares of enGene during the 2nd quarter valued at about $36,000. Paloma Partners Management Co purchased a new stake in shares of enGene in the second quarter valued at about $38,000. Finally, Jump Financial LLC acquired a new stake in enGene during the fourth quarter worth about $121,000. 64.16% of the stock is owned by hedge funds and other institutional investors.

About enGene

(Get Free Report)

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

Further Reading